loading...| Preferred Name |
Pentoxifylline |
|
| Synonyms |
3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione Oxpentifylline PENTOXIFYLLINE pentoxifylline Pentoxyphylline Pentoxifylline PTX Trental |
|
| Definitions |
A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C733 |
|
| ALT_DEFINITION |
A drug used to prevent blood clotting and as a treatment that may help decrease weight loss in people with cancer. |
|
| CAS_Registry |
6493-05-6 |
|
| Chemical_Formula |
C13H18N4O3 |
|
| code |
C733 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC |
|
| DEFINITION |
A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses. |
|
| Display_Name |
Pentoxifylline |
|
| FDA_UNII_Code |
SD6QCT3TSU |
|
| FULL_SYN |
3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione Oxpentifylline PENTOXIFYLLINE pentoxifylline Pentoxyphylline Pentoxifylline PTX Trental |
|
| Is_Value_For_GDC_Property | ||
| label |
Pentoxifylline |
|
| Legacy Concept Name |
Pentoxifylline |
|
| Maps_To |
Pentoxifylline |
|
| NCI_Drug_Dictionary_ID |
41432 |
|
| NSC Number |
637086 |
|
| PDQ_Closed_Trial_Search_ID |
41432 |
|
| PDQ_Open_Trial_Search_ID |
41432 |
|
| Preferred_Name |
Pentoxifylline |
|
| prefixIRI |
Thesaurus:C733 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0030899 |
|
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C744 |